on Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagonist Therapeutics Highlights Rusfertide at ASH Meeting
Protagonist Therapeutics, Inc. is set to present new clinical data on rusfertide for polycythemia vera at the 67th Annual American Society of Hematology Meeting in Orlando, Florida. The event, taking place from December 6-9, 2025, will feature four significant presentations including key findings from the Phase 3 VERIFY study.
Dr. Andrew Kuykendall will present data indicating the durability of response and safety of rusfertide over 52 weeks. Dr. Aniket Bankar will discuss patient-reported outcomes, while Dr. Joseph Shatzel's poster will focus on dermatologic examinations in polycythemia vera patients. Additionally, Dr. Naveen Pemmajaru will present long-term treatment results with rusfertide based on the THRIVE Extension Study.
Protagonist Therapeutics continues its collaborative efforts with Takeda Pharmaceuticals to advance rusfertide's development for rare blood disorders.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Protagonist Therapeutics, Inc. news